Shenzhen Salubris Pharmaceuticals Co: Q3 2025 saw 15.85% revenue growth and 30.19% net profit increase, led by new products

About this update from Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A

Q3 2025 revenue rose 15.85% YoY to ¥1.11 billion, with net profit up 30.19% to ¥215.63 million. New products drove growth, R&D pipeline expanded, and cash flow from operations declined 9.07% YoY.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A